Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38

por Mathijssen, R H J, Verweij, J, Loos, W J, de Bruijn, P, Nooter, K, Sparreboom, A
Publicado 2002

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.

por Ma, J., Maliepaard, M., Nooter, K., Loos, W. J., Kolker, H. J., Verweij, J., Stoter, G., Schellens, J. H.
Publicado 1998

Factors affecting pharmacokinetic variability of oral topotecan: a population analysis

por Léger, F, Loos, W J, Fourcade, J, Bugat, R, Goffinet, M, Mathijssen, R H J, Verweij, J, Sparreboom, A, Chatelut, E
Publicado 2004

Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in pa...

por Hamberg, P, Steeghs, N, Loos, W J, van de Biessen, D, den Hollander, M, Tascilar, M, Verweij, J, Gelderblom, H, Sleijfer, S
Publicado 2010

Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1–5 of a 3-weekly cycle in patients with advanced solid tumours

por de Jonge, M J A, Kaye, S, Verweij, J, Brock, C, Reade, S, Scurr, M, van Doorn, L, Verheij, C, Loos, W, Brindley, C, Mistry, P, Cooper, M, Judson, I
Publicado 2004

Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer

por Gelderblom, H, Sparreboom, A, Jonge, M J A de, Loos, W J, Wilms, E, Mantel, M A, Hennis, B, Camlett, I, Verweij, J, Burg, M E L van der
Publicado 2001